Admission to Trading on the Main Market of the LSE
Summary by AI BETAClose X
29 January 2026
CVS GROUP plc
("CVS" or the "Company" and, together with its subsidiaries, the "Group")
Admission to trading on the Main Market of the London Stock Exchange and AIM cancellation
Further to its announcement on 23 January 2026, CVS is pleased to announce that the Company's ordinary shares ("Ordinary Shares") will be admitted to the Equity Shares (Commercial Companies) category of the Official List maintained by the Financial Conduct Authority ("FCA") and to trading on the Main Market of the London Stock Exchange (together, "Admission") at 8:00am today and simultaneously cancelled from trading on AIM.
The Company is not offering any new Ordinary Shares nor any other securities in connection with the proposed Admission. Following Admission, the Ordinary Shares will continue to be registered with their existing ISIN of GB00B2863827 and the Company's ticker symbol will continue to be CVSG.
On Admission, the total number of Ordinary Shares in issue will be 70,156,093. There are no Ordinary Shares held in Treasury. The aforementioned figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
The Company's shareholders should consult their own professional advisers regarding the consequences of Admission on their personal tax position.
David Wilton, Non-Executive Chair, commented:
"Today marks an important milestone for CVS as we join the Main Market of the London Stock Exchange. The move reflects our confidence in the Group's future and our commitment to delivering long-term value for all stakeholders. It will provide access to deeper pools of capital across a broader range of investors, offer the potential for index inclusion and improvement in trading liquidity, and enhance our corporate profile, positioning CVS for the next phase of growth.
"I would like to take this opportunity to thank our shareholders for their continued support, particularly through the challenges faced by the wider sector in recent years. We are confident in the opportunities ahead and remain committed to building on this strong foundation and delivering sustainable growth."
"I would also like to take this opportunity to thank CVS colleagues for their continued dedication and support in providing care to our clients and their animals"
Contacts
CVS Group plc via Camarco
Richard Fairman, CEO
Robin Alfonso, CFO
Paul Higgs, Chief Veterinary Officer
Charlotte Page, Head of Investor Relations
Berenberg (Sponsor & Joint Broker) +44 (0)20 3207 7800
Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing
Peel Hunt LLP (Joint Broker) +44 (0)20 7418 8900
Christopher Golden / James Steel / Andrew Clark
Camarco (Financial PR) cvsg@camarco.co.uk
Ginny Pulbrook +44 (0)7961 315 138
Letaba Rimell
Tilly Butcher
About CVS Group plc (www.cvsukltd.co.uk)
CVS Group is a leading provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical and support teams at the core of its strategy.
The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an Online Retail Business.
The Group employs c.8,900 personnel, including c.2,500 veterinary surgeons and c.3,300 nurses and patient care assistants.
Important notices
This announcement contains statements that are, or may be deemed to be, "forward- looking statements". These forward-looking statements can be identified by the use of forward‑looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "plans", "goal", "target", "aim", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. All statements other than statements of historical facts included in this announcement, including those regarding the Company's strategy, plans and objectives and the anticipated Admission are forward-looking statements. Readers are cautioned not to place undue reliance on such statements. Forward-looking statements involve a number of known and unknown risks, uncertainties and other factors, many of which are difficult to predict and generally beyond the control of CVS. These forward-looking statements speak only as of the date of this announcement. CVS expressly disclaims any obligation or undertaking to update or revise any forward-looking statement (except to the extent legally required).
Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), which is authorised and regulated by the German Federal Financial Supervisory Authority and in the United Kingdom is subject to limited regulation by the FCA, is acting exclusively for the Company as Sponsor and no one else in connection with Admission and it will not regard any other person as a client in relation to Admission and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to Admission or any other transaction, matter, or arrangement referred to in this announcement.
This announcement has been issued by, and is the sole responsibility of, the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Berenberg or by any of their affiliates, partners, directors, officers, employees, advisers or agents as to or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund